Metropolis Healthcare Limited - Q4 FY25 Update

In Quarter 4 of this year, the healthcare industry faced weaker-than-usual performance across multiple sectors. The acute testing segment experienced a slowdown due to changes in weather conditions, resulting in reduced outpatient visits resulting in lower patient volumes. Additionally, lower elective procedures in major metropolitan hospitals affected our specialty testing business. The industry's challenges led to a subdued quarter, impacting both quarterly and annual performance.

Despite these industry-wide challenges, the company achieved double-digit revenue growth in Q4FY25. While the acute care segment experienced a slowdown, the wellness segment continued to show robust growth.

Key highlights of Q4FY25:

Revenues grew by approx. 10% on a Y-o-Y basis. Revenue growth was driven by patient volume growth, test volume growth and change in product mix coupled with realization benefits.

B2C revenues grew at approx. 14% on a Y-o-Y basis on account of consumer experience and expansion of service network.

Operational EBITDA for the current quarter has grown marginally lower due to higher material costs and reduced revenue growth. Reported EBIDTA is lower due to one-time costs including acquisition costs for Core Diagnostics & Scientific Pathology and lower margin from Core Diagnostics.

The Company is debt free & has cash reserves of approx. INR 112 crores post paying towards acquisition amounting to INR 130 crores as on March 31, 2025.

The quarterly business update is on a consolidated basis including financial of Core Diagnostics for 11 days of operations postacquisition. EBIDTA for Core Diagnostics is break-even. The financial results of Q4FY25 are subject to revieww by Auditors.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended March 31, 2025. A detailed information update will follow once the Board of Directors approves the financial results for Q4FY25.

Shares of Metropolis Healthcare Limited was last trading in BSE at Rs. 1550.20 as compared to the previous close of Rs. 1583.80. The total number of shares traded during the day was 4829 in over 626 trades.

The stock hit an intraday high of Rs. 1571.40 and intraday low of 1539.00. The net turnover during the day was Rs. 7531702.00.

Source : Equity Bulls

Keywords

MetropolisHealthcare INE112L01020 HealthcareServices BusinessUpdate Q4FY25